End-stage renal disease in lupus: disease activity, dialysis, and the outcome of transplantation.
Lupus nephritis remains a major cause of morbidity in SLE. Approximately 10% of patients with SLE develop end-stage renal disease (ESRD). In most SLE patients, disease activity diminishes as ESRD approaches. Consequently, the survival of SLE patients on dialysis (both hemo- and peritoneal) appears to be comparable to that of non-SLE patients. However, the role of antiphospholipid (aPL) antibodies in causing dialysis-related morbidity among patients with SLE requires further investigation. In contrast to the outcomes of dialysis, recent evidence suggests that renal transplantation outcomes among SLE patients are inferior to those of non-SLE patients, primarily because of the risk of recurrent lupus nephritis in the allograft and the effect of aPL-related events on transplantation outcomes. Future avenues of investigation should be directed at developing better strategies to manage and prevent these complications.
Stone
J H
JH
Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA.
D018450:Disease Progression; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D016030:Kidney Transplantation; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000628:therapy*; D008181:Lupus Nephritis / Q000150:complications / Q000628:therapy; D006435:Renal Dialysis